全文获取类型
收费全文 | 876篇 |
免费 | 79篇 |
专业分类
955篇 |
出版年
2023年 | 3篇 |
2022年 | 5篇 |
2021年 | 13篇 |
2020年 | 4篇 |
2019年 | 16篇 |
2018年 | 5篇 |
2017年 | 16篇 |
2016年 | 26篇 |
2015年 | 28篇 |
2014年 | 33篇 |
2013年 | 49篇 |
2012年 | 53篇 |
2011年 | 60篇 |
2010年 | 51篇 |
2009年 | 43篇 |
2008年 | 53篇 |
2007年 | 54篇 |
2006年 | 51篇 |
2005年 | 59篇 |
2004年 | 61篇 |
2003年 | 52篇 |
2002年 | 29篇 |
2001年 | 10篇 |
2000年 | 3篇 |
1999年 | 5篇 |
1998年 | 15篇 |
1997年 | 18篇 |
1996年 | 5篇 |
1995年 | 10篇 |
1994年 | 6篇 |
1993年 | 6篇 |
1992年 | 11篇 |
1991年 | 9篇 |
1990年 | 4篇 |
1989年 | 5篇 |
1988年 | 7篇 |
1987年 | 8篇 |
1986年 | 5篇 |
1985年 | 3篇 |
1984年 | 4篇 |
1983年 | 9篇 |
1982年 | 5篇 |
1981年 | 3篇 |
1980年 | 6篇 |
1978年 | 5篇 |
1977年 | 4篇 |
1975年 | 5篇 |
1974年 | 4篇 |
1972年 | 3篇 |
1970年 | 3篇 |
排序方式: 共有955条查询结果,搜索用时 15 毫秒
71.
Ebensen T Link C Riese P Schulze K Morr M Guzmán CA 《Journal of immunology (Baltimore, Md. : 1950)》2007,179(4):2065-2073
The glycolipid alpha-galactosylceramide (alphaGalCer) has immunomodulatory properties, which have been exploited to combat cancer, chronic inflammatory diseases, and infections. However, its poor solubility makes alphaGalCer a suboptimal compound for in vivo applications. In this study, a pegylated derivative of alphaGalCer is characterized, which exhibits improved physical and biological properties. The new compound, alphaGalCerMPEG, is water-soluble and retains the specificity for the CD1d receptor of alphaGalCer. The in vitro stimulatory properties on immune cells (e.g., dendritic cells and splenocytes) are maintained intact, even when tested at a 33-fold lower concentration of the active moiety than alphaGalCer. NK cells isolated from mice treated with alphaGalCerMPEG also had stronger cytotoxic activity on YAC-1 cells than those obtained from animals receiving either alphaGalCer or CpG. Intranasal immunization studies performed in mice showed that alphaGalCerMPEG exerts stronger adjuvant activities than the parental compound alphaGalCer when tested at 0.35 vs 11.7 nM/dose. Coadministration of beta-galactosidase with alphaGalCerMPEG resulted not only in high titers of Ag-specific Abs in serum (i.e., 1:512,000), but also in the stimulation of stronger Th2 and secretory IgA responses, both at local and remote mucosal effector sites (i.e., nose, lung, and vagina). The new synthetic derivative alphaGalCerMPEG represents a promising tool for the development of immune interventions against infectious and noninfectious diseases. 相似文献
72.
Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus 总被引:1,自引:0,他引:1 下载免费PDF全文
Lavillette D Pécheur EI Donot P Fresquet J Molle J Corbau R Dreux M Penin F Cosset FL 《Journal of virology》2007,81(16):8752-8765
Infection of eukaryotic cells by enveloped viruses requires the merging of viral and cellular membranes. Highly specific viral surface glycoproteins, named fusion proteins, catalyze this reaction by overcoming inherent energy barriers. Hepatitis C virus (HCV) is an enveloped virus that belongs to the genus Hepacivirus of the family Flaviviridae. Little is known about the molecular events that mediate cell entry and membrane fusion for HCV, although significant progress has been made due to recent developments in infection assays. Here, using infectious HCV pseudoparticles (HCVpp), we investigated the molecular basis of HCV membrane fusion. By searching for classical features of fusion peptides through the alignment of sequences from various HCV genotypes, we identified six regions of HCV E1 and E2 glycoproteins that present such characteristics. We introduced conserved and nonconserved amino acid substitutions in these regions and analyzed the phenotype of HCVpp generated with mutant E1E2 glycoproteins. This was achieved by (i) quantifying the infectivity of the pseudoparticles, (ii) studying the incorporation of E1E2 and their capacity to mediate receptor binding, and (iii) determining their fusion capacity in cell-cell and liposome/HCVpp fusion assays. We propose that at least three of these regions (i.e., at positions 270 to 284, 416 to 430, and 600 to 620) play a role in the membrane fusion process. These regions may contribute to the merging of viral and cellular membranes either by interacting directly with lipid membranes or by assisting the fusion process through their involvement in the conformational changes of the E1E2 complex at low pH. 相似文献
73.
Carter PH Brown GD Friedrich SR Cherney RJ Tebben AJ Lo YC Yang G Jezak H Solomon KA Scherle PA Decicco CP 《Bioorganic & medicinal chemistry letters》2007,17(19):5455-5461
A new series of CCR2 antagonists has been discovered that incorporates intramolecular hydrogen bonding as a strategy for rigidifying the scaffold. The structure-activity relationship was established through initial systematic modification of substitution pattern and chain length, followed by independent optimization of three different substituents (benzylamine, carboxamide, and benzamide). Several of the acyclic compounds display 10-30 nM binding affinity for CCR2. Moreover, these antagonists are able to block both MCP-1-induced Ca(2+) flux and monocyte chemotaxis, and are selective for binding to CCR2 over CCR1 and CCR3. 相似文献
74.
Zheng C Cao G Xia M Feng H Glenn J Anand R Zhang K Huang T Wang A Kong L Li M Galya L Hughes RO Devraj R Morton PA Rogier DJ Covington M Baribaud F Shin N Scherle P Diamond S Yeleswaram S Vaddi K Newton R Hollis G Friedman S Metcalf B Xue CB 《Bioorganic & medicinal chemistry letters》2011,21(5):1442-1446
We report the discovery of a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist (3S,4S)-N-[(1R,3S)-3-isopropyl-3-({4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)cyclopentyl]-3-methoxytetrahydro-2H-pyran-4-amine (19). After evaluation in 28-day toxicology studies, compound 19 (INCB10820/PF-4178903) was selected as a clinical candidate. 相似文献
75.
76.
77.
78.
79.
80.
Douglas H. Smith Peggy Winters-Digiacinto Misrach Mitiku Sara O'Rourke Faruk Sinangil Terri Wrin David C. Montefiori Phillip W. Berman 《PloS one》2010,5(8)